Prostate Cancer


The Prostate Cancer's Resource page is a collaborative project of NeedyMeds and ZERO - The End of Prostate Cancer. It is intended to provide information on Prostate Cancer and to help those with Prostate Cancer find assistance paying for their medications.

Prostate cancer is the most commonly diagnosed cancer in American men after skin cancer. One in eight American men will be diagnosed with prostate cancer in his lifetime. Prostate cancer is a cancer that starts in the prostate, a small walnut-shaped gland in the male reproductive system. Like all cancers, prostate cancer begins in cells, the building blocks that make up all tissue and organs of the body, including the prostate. Normal cells grow, divide, and die on a regular schedule. Sometimes something goes wrong with this process and the cells don't die as they should. Instead, they create a growth or tumor. During the early stages of prostate cancer, there are no symptoms, so screenings and yearly check-ups are critically important. When diagnosed at an early stage, prostate cancer can usually be treated successfully. In fact, almost 100 percent of men diagnosed with early-stage prostate cancer today will be alive in five years. For more information about whether you are at risk, what the diagnosis process looks like, treatment options, and next steps, visit ZERO's website.

ZERO recommends all men speak to their doctor regarding their risk for the disease and testing for prostate cancer. The greatest risk factors for developing prostate cancer are age, race, and family history.

ZERO - The End of Prostate Cancer and NeedyMeds neither promote nor endorse the therapies listed below nor the supporters of this page. This page is for educational purposes only.

Click HERE to learn more about how to use the information on the website and click HERE for more details on pharmaceutical patient assistance programs.

Medications used in the treatment of Prostate Cancer

Click on the drug name to see what programs are available for the drug:

RX Outreach Additional Resources: